Management of recurrent hepatitis C after liver transplantation: A concise review

G. Szabó, Eliezer Katz, Herbert L. Bonkovsky

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interfferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation. (C) 2000 by Am. Coll. of Gastroenterology.

Original languageEnglish
Pages (from-to)2164-2170
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume95
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Hepatitis C
Liver Transplantation
Ribavirin
Transplants
Therapeutics
Gastroenterology
Hepacivirus
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Management of recurrent hepatitis C after liver transplantation : A concise review. / Szabó, G.; Katz, Eliezer; Bonkovsky, Herbert L.

In: American Journal of Gastroenterology, Vol. 95, No. 9, 2000, p. 2164-2170.

Research output: Contribution to journalReview article

Szabó, G. ; Katz, Eliezer ; Bonkovsky, Herbert L. / Management of recurrent hepatitis C after liver transplantation : A concise review. In: American Journal of Gastroenterology. 2000 ; Vol. 95, No. 9. pp. 2164-2170.
@article{fc06c865cb8c44068c9fb505054025a5,
title = "Management of recurrent hepatitis C after liver transplantation: A concise review",
abstract = "Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interfferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation. (C) 2000 by Am. Coll. of Gastroenterology.",
author = "G. Szab{\'o} and Eliezer Katz and Bonkovsky, {Herbert L.}",
year = "2000",
doi = "10.1016/S0002-9270(00)01088-1",
language = "English",
volume = "95",
pages = "2164--2170",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Management of recurrent hepatitis C after liver transplantation

T2 - A concise review

AU - Szabó, G.

AU - Katz, Eliezer

AU - Bonkovsky, Herbert L.

PY - 2000

Y1 - 2000

N2 - Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interfferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation. (C) 2000 by Am. Coll. of Gastroenterology.

AB - Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interfferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation. (C) 2000 by Am. Coll. of Gastroenterology.

UR - http://www.scopus.com/inward/record.url?scp=0033825825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033825825&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(00)01088-1

DO - 10.1016/S0002-9270(00)01088-1

M3 - Review article

C2 - 11007212

AN - SCOPUS:0033825825

VL - 95

SP - 2164

EP - 2170

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -